Novartis has agreed to acquire Myricx Bio for $1.1 billion upfront, with up to $400 million in milestone payments, reinforcing strong pharmaceutical demand for next-generation antibody-drug conjugate (“ADC”) technologies. The transaction, announced this week, provides Novartis access to Myricx Bio’s novel N-myristoyltransferase inhibitor (“NMTi”) payload platform and two lead ADC programs, reflecting continued industry demand for innovative antibody technologies capable of addressing limitations of existing cancer therapies.
The latest deal adds to a growing list of multibillion-dollar ADC and T-cell engager (“TCE”) transactions, highlighting sustained strategic investment in differentiated antibody platforms. Recent examples include Jazz Pharmaceuticals’ collaboration with AbCellera, Gilead Sciences’ acquisition of Tubulis, and multiple multibillion-dollar ADC licensing agreements. These deals underscore the pharmaceutical industry’s commitment to advancing antibody-based therapeutics, particularly in oncology.
VERAXA Biotech (NASDAQ: VRXA) operates in one of biotechnology’s most active partnering environments. The company is advancing proprietary antibody therapeutics spanning both ADCs and TCEs through its patented BiTAC platform. This positions VERAXA within two therapeutic categories that continue to attract significant pharmaceutical investment, strategic collaborations, and acquisition activity. The Novartis-Myricx acquisition serves as a key validation of the ADC space, potentially increasing interest in companies like VERAXA that are developing next-generation antibody platforms.
VERAXA’s BiTAC platform is designed to enable the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. By leveraging its suite of transformative technologies and quality-by-design principles, VERAXA aims to rapidly advance its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
For investors, the Novartis transaction signals robust market appetite for differentiated ADC technologies, which could enhance the valuation and strategic appeal of companies with similar capabilities. VERAXA’s focus on both ADCs and TCEs positions it to potentially benefit from partnerships or acquisitions as pharmaceutical companies seek to bolster their oncology pipelines. The company’s latest news and updates are available in its newsroom at http://ibn.fm/VRXA.
